CRL Charles River Laboratories International Inc

Price (delayed)

$227.95

Market cap

$11.71B

P/E Ratio

24.59

Dividend/share

N/A

EPS

$9.27

Enterprise value

$14.49B

Charles River Laboratories, Inc., is an American corporation specializing in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted ...

Highlights
The equity is up by 21% year-on-year and by 9% since the previous quarter
The quick ratio is up by 11% year-on-year and by 4.2% since the previous quarter
The price to earnings (P/E) is 22% lower than the 5-year quarterly average of 31.4 but 10% higher than the last 4 quarters average of 22.3
CRL's revenue is up by 3.9% year-on-year but it is down by 2% since the previous quarter
Charles River Laboratories International's debt has increased by 6% QoQ
The EPS fell by 3.1% YoY

Key stats

What are the main financial stats of CRL
Market
Shares outstanding
51.35M
Market cap
$11.71B
Enterprise value
$14.49B
Valuations
Price to book (P/B)
3.25
Price to sales (P/S)
2.83
EV/EBIT
20.35
EV/EBITDA
14.12
EV/Sales
3.51
Earnings
Revenue
$4.13B
EBIT
$712.25M
EBITDA
$1.03B
Free cash flow
$365.37M
Per share
EPS
$9.27
Free cash flow per share
$7.13
Book value per share
$70.12
Revenue per share
$80.61
TBVPS
$82.69
Balance sheet
Total assets
$8.2B
Total liabilities
$4.54B
Debt
$3.07B
Equity
$3.6B
Working capital
$553.58M
Liquidity
Debt to equity
0.85
Current ratio
1.52
Quick ratio
1
Net debt/EBITDA
2.72
Margins
EBITDA margin
24.9%
Gross margin
36.4%
Net margin
11.5%
Operating margin
14.9%
Efficiency
Return on assets
6.1%
Return on equity
14.3%
Return on invested capital
12.3%
Return on capital employed
10%
Return on sales
17.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRL stock price

How has the Charles River Laboratories International stock price performed over time
Intraday
0.52%
1 week
-3.38%
1 month
-16.37%
1 year
13.46%
YTD
-3.57%
QTD
-15.87%

Financial performance

How have Charles River Laboratories International's revenue and profit performed over time
Revenue
$4.13B
Gross profit
$1.5B
Operating income
$617.26M
Net income
$474.62M
Gross margin
36.4%
Net margin
11.5%
The operating margin fell by 9% YoY and by 3.2% QoQ
Charles River Laboratories International's net margin has decreased by 6% YoY
CRL's operating income is down by 5% YoY and by 4.8% QoQ
CRL's revenue is up by 3.9% year-on-year but it is down by 2% since the previous quarter

Growth

What is Charles River Laboratories International's growth rate over time

Valuation

What is Charles River Laboratories International stock price valuation
P/E
24.59
P/B
3.25
P/S
2.83
EV/EBIT
20.35
EV/EBITDA
14.12
EV/Sales
3.51
The price to earnings (P/E) is 22% lower than the 5-year quarterly average of 31.4 but 10% higher than the last 4 quarters average of 22.3
The EPS fell by 3.1% YoY
The price to book (P/B) is 35% lower than the 5-year quarterly average of 5.0 and 2.1% lower than the last 4 quarters average of 3.3
The equity is up by 21% year-on-year and by 9% since the previous quarter
The P/S is 20% lower than the 5-year quarterly average of 3.5 but 8% higher than the last 4 quarters average of 2.6
CRL's revenue is up by 3.9% year-on-year but it is down by 2% since the previous quarter

Efficiency

How efficient is Charles River Laboratories International business performance
The ROE has contracted by 20% YoY and by 4.7% from the previous quarter
The company's return on assets fell by 8% YoY
The company's return on invested capital fell by 7% QoQ
The ROS fell by 3.4% QoQ

Dividends

What is CRL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRL.

Financial health

How did Charles River Laboratories International financials performed over time
The company's total assets is 81% higher than its total liabilities
Charles River Laboratories International's current ratio has increased by 15% YoY and by 4.8% from the previous quarter
The quick ratio is up by 11% year-on-year and by 4.2% since the previous quarter
Charles River Laboratories International's debt is 15% lower than its equity
The equity is up by 21% year-on-year and by 9% since the previous quarter
Charles River Laboratories International's debt to equity has decreased by 18% YoY and by 3.4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.